Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MBRX Moleculin Biotech	$0.90 -1.2%	$0.94	$0.40 ▼ $4.90	$12.67M	1.64	1.48 million shs	106,663 shs
NEUP Neuphoria Therapeutics Inc. - Common Stock	$6.55 +1.1%	$5.34	$2.12 ▼ $12.72	$12.18M	0.26	343,981 shs	9,338 shs
SNPX Synaptogenix	$2.46 -1.6%	$2.30	$1.84 ▼ $5.05	$3.47M	1.06	22,389 shs	48,645 shs
UBX Unity Biotechnology	$0.68	$0.92	$0.66 ▼ $3.10	$11.70M	1.28	130,064 shs	178,891 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MBRX Moleculin Biotech	0.00%	-5.72%	-11.23%	-30.50%	-79.62%
NEUP Neuphoria Therapeutics Inc. - Common Stock	0.00%	-3.39%	+31.00%	+25.96%	+654,999,900.00%
SNPX Synaptogenix	0.00%	+10.07%	-2.57%	-7.52%	-43.96%
UBX Unity Biotechnology	0.00%	-12.71%	-38.18%	-60.23%	-56.69%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MBRX Moleculin Biotech	1.985 of 5 stars	3.5	2.0	0.0	1.9	0.0	1.3
NEUP Neuphoria Therapeutics Inc. - Common Stock	1.5982 of 5 stars	3.5	0.0	0.0	2.2	0.0	0.6
SNPX Synaptogenix	2.5797 of 5 stars	3.5	5.0	0.0	2.2	0.0	0.6
UBX Unity Biotechnology	4.3789 of 5 stars	3.3	4.0	4.7	3.2	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MBRX Moleculin Biotech	3.00	Buy	$6.00	569.19% Upside
NEUP Neuphoria Therapeutics Inc. - Common Stock	3.00	Buy	$21.00	220.61% Upside
SNPX Synaptogenix	3.00	Buy	$14.00	469.11% Upside
UBX Unity Biotechnology	2.50	Moderate Buy	$3.75	451.47% Upside

Current Analyst Ratings Breakdown

Latest SNPX, UBX, NEUP, and MBRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/27/2025	UBX Unity Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$4.00 ➝ $2.00
5/16/2025	UBX Unity Biotechnology	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$6.00 ➝ $1.00
4/23/2025	UBX Unity Biotechnology	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
4/23/2025	UBX Unity Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
3/25/2025	MBRX Moleculin Biotech	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$4.00
3/25/2025	UBX Unity Biotechnology	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $4.00
3/24/2025	MBRX Moleculin Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
3/24/2025	UBX Unity Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $4.00
3/10/2025	UBX Unity Biotechnology	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00
3/10/2025	UBX Unity Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
3/3/2025	MBRX Moleculin Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00

(Data available from 5/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MBRX Moleculin Biotech	N/A	N/A	N/A	N/A	$11.70 per share	N/A
NEUP Neuphoria Therapeutics Inc. - Common Stock	$15.66M	0.79	N/A	N/A	$7.82 per share	0.84
SNPX Synaptogenix	N/A	N/A	N/A	N/A	$25.27 per share	N/A
UBX Unity Biotechnology	$240K	48.77	N/A	N/A	$1.69 per share	0.40

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MBRX Moleculin Biotech	-$29.77M	N/A	0.00	N/A	N/A	N/A	-157.44%	-97.16%	8/12/2025 (Estimated)
NEUP Neuphoria Therapeutics Inc. - Common Stock	-$15.49M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
SNPX Synaptogenix	-$6.04M	-$10.08	N/A	∞	N/A	N/A	-42.14%	-29.42%	N/A
UBX Unity Biotechnology	-$39.86M	-$1.62	N/A	N/A	N/A	N/A	-119.70%	-45.86%	8/5/2025 (Estimated)

Latest SNPX, UBX, NEUP, and MBRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/20/2025	Q3 2025	NEUP Neuphoria Therapeutics Inc. - Common Stock	-$0.47	$6.55	+$7.02	$6.55	N/A	$15.00 million
5/15/2025	Q1 2025	SNPX Synaptogenix	N/A	$0.04	N/A	$0.04	N/A	N/A
5/13/2025	Q1 2025	MBRX Moleculin Biotech	-$0.71	-$0.69	+$0.02	-$0.69	N/A	N/A
4/22/2025	Q1 2025	UBX Unity Biotechnology	-$0.43	-$0.43	N/A	-$0.43	N/A	N/A
3/27/2025	Q4 2024	SNPX Synaptogenix	-$2.06	-$4.36	-$2.30	-$4.36	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MBRX Moleculin Biotech	N/A	N/A	N/A	N/A	N/A
NEUP Neuphoria Therapeutics Inc. - Common Stock	N/A	N/A	N/A	N/A	N/A
SNPX Synaptogenix	N/A	N/A	N/A	N/A	N/A
UBX Unity Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MBRX Moleculin Biotech	N/A	2.08	2.08
NEUP Neuphoria Therapeutics Inc. - Common Stock	N/A	2.06	3.30
SNPX Synaptogenix	N/A	65.34	65.34
UBX Unity Biotechnology	N/A	3.45	3.45

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MBRX Moleculin Biotech	15.52%
NEUP Neuphoria Therapeutics Inc. - Common Stock	15.90%
SNPX Synaptogenix	10.34%
UBX Unity Biotechnology	29.49%

Insider Ownership

Company	Insider Ownership
MBRX Moleculin Biotech	1.90%
NEUP Neuphoria Therapeutics Inc. - Common Stock	0.69%
SNPX Synaptogenix	2.73%
UBX Unity Biotechnology	5.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MBRX Moleculin Biotech	20	14.13 million	3.86 million	Not Optionable
NEUP Neuphoria Therapeutics Inc. - Common Stock	N/A	1.88 million	1.75 million	N/A
SNPX Synaptogenix	4	1.39 million	1.32 million	Not Optionable
UBX Unity Biotechnology	60	17.21 million	15.87 million	Optionable

SNPX, UBX, NEUP, and MBRX Headlines

Recent News About These Companies

HC Wainwright Issues Positive Estimate for UBX Earnings

May 30 at 1:18 AM | americanbankingnews.com

Unity Biotechnology (NASDAQ:UBX) Earns Neutral Rating from HC Wainwright

May 29 at 1:15 AM | americanbankingnews.com

HC Wainwright & Co. Downgrades Unity Biotechnology (UBX)

May 28, 2025 | msn.com

Unity Biotechnology (UBX) was downgraded to a Hold Rating at Mizuho Securities

May 18, 2025 | theglobeandmail.com

Bay Area biotech company Unity lays off every single worker, including CEO

May 7, 2025 | msn.com

Bay Area biotech company Unity, once worth $700M, lays off entire remaining workforce

May 5, 2025 | msn.com

South San Francisco biotech company lays off entire workforce, including CEO

May 5, 2025 | msn.com

Unity disbands workforce as it searches for strategic path forward, while Mammoth cuts 24 roles

May 5, 2025 | fiercebiotech.com

UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting

May 1, 2025 | globenewswire.com

NEJM Evidence publishes results from Phase 2 BEHOLD study of UBX1325

April 25, 2025 | ophthalmologytimes.com

UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates

April 22, 2025 | globenewswire.com

Unity Biotechnology price target lowered to $4 from $8 at H.C. Wainwright

March 26, 2025 | markets.businessinsider.com

Unity Biotechnology price target lowered to $4 from $6 at Chardan

March 26, 2025 | markets.businessinsider.com

Unity Biotechnology announces results from ASPIRE Phase 2b study in DME

March 25, 2025 | markets.businessinsider.com

Unity reports topline outcomes from trial of diabetic macular oedema therapy

March 25, 2025 | msn.com

UNITY Biotechnology tanks on mixed results for eye disease drug

March 25, 2025 | thepharmaletter.com

UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study

March 25, 2025 | zacks.com

UNITY Biotechnology Shares Drop 33% After Phase 2b Trial Data on UBX1325 in Diabetic Macular Edema

March 24, 2025 | finance.yahoo.com

Unity Biotechnology releases topline results from phase 2b ASPIRE trial of UBX1325 in patients with diabetic macular edema

March 24, 2025 | ophthalmologytimes.com

UNITY Biotechnology tanks after failing to meet goal in eye disorder treatment trial

March 24, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNPX, UBX, NEUP, and MBRX Company Descriptions

Moleculin Biotech NASDAQ:MBRX

$0.90 -0.01 (-1.23%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$0.87 -0.03 (-2.97%)

As of 05/30/2025 07:29 PM Eastern

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Neuphoria Therapeutics Inc. - Common Stock NASDAQ:NEUP

$6.55 +0.07 (+1.08%)

As of 05/30/2025 03:16 PM Eastern

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Synaptogenix NASDAQ:SNPX

$2.46 -0.04 (-1.60%)

Closing price 05/30/2025 03:59 PM Eastern

Extended Trading

$2.57 +0.11 (+4.47%)

As of 05/30/2025 07:44 PM Eastern

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York.

Unity Biotechnology NASDAQ:UBX

$0.68 0.00 (0.00%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$0.69 +0.01 (+1.62%)

As of 05/30/2025 07:45 PM Eastern

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time